Atrium Therapeutics has officially launched as a newly independent, publicly traded company dedicated to developing RNA therapeutics that directly target rare genetic cardiomyopathies. The company was formed in connection with Avidity Biosciences’ acquisition by Novartis and begins operations with approximately $270 million in cash and cash equivalents. Atrium is led by Kathleen Gallagher as President and CEO and enters the market with two precision cardiology candidates and additional undisclosed research programs in development.
Atrium’s strategy centers on delivering RNA-based medicines directly to the heart to address the root biological drivers of disease—rather than simply managing symptoms. Its two lead programs target severe, progressive, autosomal dominant cardiomyopathies with no approved therapies that modify the underlying cause: ATR 1072 for PRKAG2 syndrome and ATR 1086 for phospholamban (PLN) cardiomyopathy.
Both conditions are life-threatening and driven by genetic mutations that disrupt normal cardiac function. By leveraging targeted RNA delivery technology originally developed at Avidity, Atrium aims to advance precision therapies that intervene at the molecular level in heart tissue.
The company has outlined clear development milestones. For ATR 1072, Investigational New Drug (IND)-enabling studies and chemistry, manufacturing, and controls (CMC) activities are underway, with an IND submission expected in the second half of 2026. ATR 1086 is advancing through CMC preparation and is expected to enter IND-enabling preclinical studies in 2026, with a targeted IND filing in 2027. Subject to supportive Phase 1 data, both candidates are expected to progress into clinical trials.
Beyond its initial programs, Atrium plans to expand its precision cardiology pipeline and further develop next-generation RNA delivery platforms, aiming to build a durable, innovation-driven franchise in cardiovascular genetic disease.
Click here to read the original news story.